1. Sodium-glucose cotransporter 2 inhibitors were associated with lower risk of late-onset epilepsy vs dipeptidyl peptidase-4 inhibitors.
2. They also reduced risk of status epilepticus and antiseizure medication use.
3. Findings were consistent across subgroups and sensitivity analyses.
4. Benefit was seen in patients with stroke or dementia.
5. No benefit was observed in traumatic brain injury- or tumor-related epilepsy.

Source: Epilepsia